Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.
It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival ben
Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be mad
AstraZeneca's PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, according to cost effectiveness agency NICE.<
Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved
